This article is more than 5 years old. Information may no longer be current.
BioTissue introduces procedure to treat conjunctivochalasis, restore tear reservoir
Click Here to Manage Email Alerts
BioTissue Inc. is introducing an amniotic membrane-based treatment for conjunctivochalasis dry eye at the American Society of Cataract and Refractive Surgery meeting in Boston, the company announced in a news release.
The Reservoir Restoration procedure uses cryopreserved amniotic membrane to restore the tear reservoir and tear meniscus, and inhibits metalloproteinase activity. The procedure involves the company’s proprietary AmnioGraft replacement tissue product.
“While there are currently different techniques for [conjunctivochalasis], none currently addresses the Tenon’s capsule, which new evidence suggests will lead to more successful and durable outcomes,” the release said. “This new surgical procedure offers two techniques that remove the unhealthy Tenon, one using sutures, and the other without.”
Conjunctivochalasis, a loose or deformed conjunctiva that obstructs the tear meniscus and degrades the fornix, stems from the Tenon’s capsule being degenerated or dissolved by matrix metalloproteinase. Loose or deformed conjunctival tissue infiltrates the tear reservoir and thwarts the eye from retaining tears, resulting in pain and irritation that mimic dry eye symptoms. The tissue also disrupts the tear meniscus.